Cortexin.
Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves.
Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves. Cortexin is research / preclinical, and PepCue grades its published evidence D tier (35/100). Also known as cattle brain polypeptides. This is a research reference, not medical or dosing advice.
What it is
Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves. It contains a mixture of short water-soluble peptides (roughly 1 to 10 kDa), amino acids and trace elements, and is supplied as a lyophilized powder reconstituted for intramuscular injection. Developed and marketed primarily in Russia by GEROPHARM, it is positioned as a neurotrophic and neuroprotective agent. It is used clinically within Russia and several neighboring countries for a range of neurological conditions.
How it works
Like other brain-tissue peptide preparations, Cortexin is a complex mixture, so its activity is attributed to the combined effect of many peptide-protein interactions rather than a single molecular target. Proposed mechanisms include support of neuronal energy metabolism, antioxidant and anti-apoptotic effects, and modulation of neurotrophic factors and neurotransmitter systems such as GABA and dopamine. Its low-molecular-weight peptides are claimed to cross the blood-brain barrier. These mechanisms are largely inferred from preclinical models.
Mechanism pathways
Raising growth factors that support neuronal survival, synapse formation, and plasticity.
Neurotrophic factors are proteins that keep neurons alive, guide the formation and strengthening of synapses, and support the structural changes underlying learning. The best-studied is brain-derived neurotrophic factor, which acts on the TrkB receptor tyrosine kinase to activate PI3K and Akt signalling for survival and MAPK signalling for growth, and which is required for long-term potentiation, the cellular process most closely associated with memory formation. Nerve growth factor acts similarly through TrkA. A separate system involves hepatocyte growth factor and its receptor tyrosine kinase c-Met, which in neurons is associated with dendritic spine formation and synaptogenesis. Compounds in this group approach the same idea from different angles. Several are short peptides derived from fragments of adrenocorticotropic hormone that lack the hormone's melanocortin-driven corticotropic activity, so they do not raise cortisol. Their best-characterised action in animal and cell studies is upregulation of BDNF and its TrkB receptor in the hippocampus and cortex, along with increased nerve growth factor expression, plus modulation of monoaminergic signalling and inhibition of enkephalin-degrading enzymes. One member of this subgroup is a chemically modified variant designed for greater stability, whose mechanism is inferred from the parent rather than independently established. Others are complex biological mixtures rather than single molecules, prepared from brain tissue, and their activity is attributed to many peptide interactions acting together. Proposed actions include mimicking endogenous neurotrophic factors, supporting neuronal energy metabolism, reducing excitotoxicity, and providing anti-apoptotic and antioxidant effects. Because the active components are not fully defined, batch consistency is an intrinsic issue with this format. A further compound is reported to raise BDNF transcription while inhibiting a cytokine signalling pathway, with downstream reduction of an enzyme implicated in abnormal tau phosphorylation. Another was developed to potentiate hepatocyte growth factor signalling at c-Met. Several honest caveats apply. Most of this evidence comes from rodent and cell-culture work. Some of the brain-derived mixtures are approved and widely used in certain countries while remaining unapproved and unavailable in others, and independent assessments of their clinical benefit have been mixed. For the c-Met compound, the central biochemical evidence for its proposed mechanism came from a publication that was retracted for data fabrication, and c-Met is a well-established oncology target, so chronic potentiation raises an unresolved risk question that no human study has addressed.
The evidence
The evidence base for Cortexin comes predominantly from Russian-language studies and preclinical models, with limited independent Western validation. A recent preclinical study (Kurkin et al., Biomedicines 2025) reported neurotropic effects in rat models of toxic and traumatic developmental delay. Clinical use is widespread in Russia across pediatric neurology, stroke rehabilitation and cognitive disorders, but large, blinded, international randomized trials indexed in mainstream databases are scarce. As a result, Cortexin has not been subjected to the RCT and Cochrane-level scrutiny applied to Cerebrolysin. Its efficacy claims should therefore be read with caution. The human literature is dominated by multicenter observational programs rather than randomized comparisons: the CORNELia program in chronic cerebrovascular disease with cognitive impairment and the CORTEX program in post-COVID neurological complaints are both described as observational, meaning they lack a concurrent randomized control arm, blinding, and placebo control, so improvement over time cannot be separated from natural recovery, regression to the mean or expectation effects. Comparative studies do exist within the same national literature, for example a comparison with another peptide preparation in the early recovery period after ischaemic stroke, but these are typically single-country, modest in size and published in one journal, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, closely associated with the domestic market for the drug. Preclinical support includes rodent work on antioxidant effects in chronic cerebrovascular insufficiency and a cell-culture study reporting protection of cultured rat sensory neurons from high-glucose injury. Nearly all of this literature originates in the country where the product is registered and marketed, and the manufacturer's involvement in the observational programs is a relevant consideration. What is missing is specific: no independent multinational randomized trial, no Cochrane or comparable systematic review, no published characterization of which peptides in the extract are active, and no external regulatory assessment of the manufacturing and potency standards. Cortexin sits alongside thymalin, vilon and epitalon in resting on single-country literature, while Cerebrolysin, despite its own unresolved questions, has at least been tested in independently reviewed randomized trials.
The evidence, in brief
A bovine cortex-derived polypeptide preparation, widely prescribed in Russia and neighbouring states for stroke rehabilitation, pediatric neurology and cognitive disorders. The published evidence is predominantly Russian-language and preclinical, with a recent rat study of developmental-delay models among the few English-indexed reports. Unlike Cerebrolysin it has never faced Cochrane-level scrutiny, and it is not FDA-approved.
- Kurkin DV et al.: Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental DelayBiomedicines, 2025 (PMID 40299434)
- PubMed search: cortexin neuroprotectivePubMed / NCBI
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #015
Mostly preclinical or mechanistic; little human data.
Studied in human clinical trials; evidence is meaningful.
Claim receipts
Popular claims about Cortexin, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Clinical use in its home market is widespread, but the human literature is dominated by observational multicenter programs rather than randomized comparisons, so benefit over natural recovery has not been demonstrated.
Studies exist, but they are largely single-country, modest in size and concentrated in one national journal closely associated with the domestic market for the product, with no independent multinational randomized trial and no systematic review.
The supporting programs lack a randomized control arm, blinding and placebo, so improvement over time cannot be separated from natural recovery or expectation effects, and subjective cognitive outcomes are among the most placebo-responsive endpoints in medicine.
Cerebrolysin has accumulated enough independent randomized trials for two Cochrane reviews; cortexin has never been subjected to that level of scrutiny, so the two do not sit at the same evidence level.
Pediatric use is common where it is registered but has not been evaluated in independently reviewed controlled trials, and as an injected bovine tissue extract it carries hypersensitivity and repeat-course immunogenicity concerns.
Safety profile
Cortexin is generally described in its clinical literature as well tolerated when given intramuscularly, with hypersensitivity and allergic reactions being the main labeled concern. As a parenteral bovine-derived biological, theoretical risks include allergic reactions and injection-site effects, and the same category concerns apply that attach to any animal-tissue extract given by injection: immunogenicity on repeated courses, dependence on the source herd and purification process for freedom from adventitious agents, and the practical difficulty of proving batch equivalence for a mixture whose active constituents are not defined. Independent long-term safety data from outside its region of use are limited, and the observational design of most human reports means adverse events were collected without a comparator, so background rates cannot be separated from drug-related events. Use in children, which is common in the Russian pediatric neurology setting, has not been evaluated in independently reviewed controlled trials, and pediatric exposure is precisely the situation where an external safety assessment would ordinarily be required. Product acquired outside licensed pharmacy channels carries additional contamination and counterfeit risk, since injectables demand verified sterility and endotoxin control that unregulated supply cannot demonstrate. A trial-grade safety evaluation would include prospective adverse-event capture against a control arm, hypersensitivity monitoring, hepatic and renal laboratory follow-up, and anti-drug antibody testing on repeat courses. It is a prescription clinical product, not a dietary supplement.
Compound notes
- Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves, containing short water-soluble peptides (roughly 1 to 10 kDa), amino acids and trace elements.
- It is supplied as a lyophilized powder reconstituted for intramuscular injection, developed and marketed primarily in Russia by GEROPHARM.
- As a complex mixture, its activity is attributed to many combined peptide-protein interactions rather than a single target; proposed mechanisms include support of neuronal energy metabolism, antioxidant and anti-apoptotic effects, and modulation of neurotrophic factors and neurotransmitter systems.
- Evidence is predominantly Russian-language and preclinical, with limited independent Western validation.
Same general category, different source and different scrutiny. Cortexin is bovine cortex extract used mainly within Russia; cerebrolysin is porcine and has faced RCT and Cochrane-level review that cortexin has not.
- Not FDA-approved and not marketed in the United States or the European Union; it is a registered prescription medicine in Russia and several post-Soviet states.
- Hypersensitivity and allergic reactions are the main labeled concern, alongside injection-site effects expected of a parenteral bovine-derived biological.
- Independent long-term safety data from outside its region of use are limited, and efficacy claims should be read with caution.
Regulatory status
Cortexin is not FDA-approved and is not marketed in the United States or the European Union. It is a registered prescription medicine in Russia and several post-Soviet states. This summary is educational and includes no dosing information.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Polypeptide complex extracted from the cerebral cortex of cattle and calves.
- 02Contains low-molecular-weight peptides (about 1 to 10 kDa) plus amino acids and trace elements.
- 03Supplied as a lyophilized powder for intramuscular injection.
- 04Developed and used clinically in Russia by GEROPHARM, including in pediatric neurology.
- 05Evidence is mostly Russian-language and preclinical, with little independent Western RCT data.
- 06Approved in Russia and neighboring countries; not FDA-approved.
Cortexin: research formats
Choose the format you are researching to see route-specific notes.
Supplied as a lyophilized powder reconstituted for intramuscular injection. Not FDA-approved.
Cortexin is a polypeptide complex extracted from the cerebral cortex of cattle and calves, containing peptides of roughly 1 to 10 kDa along with amino acids and trace elements. It is supplied as a lyophilized powder that is reconstituted for intramuscular injection. It is a registered prescription medicine in Russia and several post-Soviet states, developed and marketed by GEROPHARM, and is not approved or marketed in the United States or the European Union.
As a registered medicine in its home markets, Cortexin has approved product information there setting out its regimens. This page does not reproduce that labeling, and no US label exists to cite.
The evidence base is mostly Russian-language and preclinical, with little independent Western randomized trial data.
Sources
Every factual claim above resolves to a real, published source.
- Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental DelayKurkin DV et al. Biomedicines, 2025 (PMID 40299434)
- PubMed literature search: cortexin neuroprotectiveSearch view illustrating the limited independent Western literature base
- Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study) (in Russian)Mashin VV, Belova LA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2023 (PMID 38147380)
- Cortexin Ameliorates High Glucose-Induced Neuropathy in Cultured Rat Sensory NeuronsYazar U, Ayar A, et al. Neuroendocrinology. 2023 (PMID 37080184)
- Antioxidant effect of cortexin, cerebrolysin and actovegin in rats with chronic cerebrovascular insufficiency (in Russian)Kurkin DV, Morkovin EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2021 (PMID 34460162)
Cite this page
PepCue. “Cortexin: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/cortexin.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.